The majority of patients in our study demonstrated signs that may be indicative of dexmedetomidine withdrawal. Peak and cumulative daily dexmedetomidine dose, rather than duration of therapy, may be associated with a higher incidence of withdrawal signs.

Regular screening of patients on prolonged dexmedetomidine infusions is recommended to ensure safe and effective use in critically ill patients.

42 patients were included in the study, with 64% of patients experiencing signs of dexmedetomidine withdrawal.

The median time on dexmedetomidine for all patients was 9.6 days, and the median dose of dexmedetomidine received was 0.8 µg/kg/hr (0.5–1 µg/kg/hr).

Indicators of withdrawal were assessed at baseline and at least daily during the dexmedetomidine wean period. Delirium was assessed using the Confusion Assessment Method for the ICU. Sedation was assessed using the Richmond Agitation-Sedation Scale.

Read More